Regulatory effects of miR-19a on MAD2 expression and tumorigenesis in gastric cancer

Gastric cancer (GC) is worldwide the sixth most diagnosed and third leading cause of cancer deaths, with poor and late prognosis, probably due to post-surgery adjuvant treatment resistance and lack of a thorough panel of prognostic markers. We have previously shown that mitotic arrest deficient 2 (MAD2, encoded by MAD2L1), a key protein of the spindle assembly checkpoint, is relevant in GC cells; its interference impairs migration and growth, while its overexpression correlates with tumorigenesi

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

Analysis of shared heritability in common disorders of the brain

Paroxysmal Cerebral Disorder

Synthesis, characterization and tumor cell growth inhibition of new transplatinum complexes with phosphane derivatives

We have reported the synthesis and characterization of two new trans platinum complexes in the phosphane series, where the phosphane ligand is triphenylphosphine [P(Ph)3] and the group in the trans configuration is represented by chiral aliphatic amines, (racemic in complex 1 and S\u2013NH2CH2CH(CH3)CH2CH3 in complex 2). The anti-proliferative activity detected in tumor cells treated with the two new complexes is more pronounced when the aliphatic amine is racemic compared to the S-enantiomer. Moreover, for both compounds, the activity is fast after cell exposure and, unlike that of cisplatin, virtually independent of the duration of cell challenge

シーボルト「NIPPON」について

貴重文物講習会（第6回） 日時:平成20年3月17日（月） 15:00- 会場:九州大学附属図書館視聴覚ホー

Hydration mechanisms of Ba-doped ye’elimite: effect of Ba/Ca ratio on hydration behavior

Manuscrito revisado de los autores, aceptado y finalmente publicado en: Construction and Building Materials 264 (2020) 120258), con DOI: https://doi.org/10.1016/j.conbuildmat.2020.120258Than stoichiometric one. However, the hydration mechanism is not well understood, in particular for the effect of Ba/Ca ratio on hydration behavior. To shed light on this issue, high purity C4-xBxA3$samples with designed element compositions (C4A3$, C3.5B0.5A3$, and C3BA3$) were prepared and their hydration processes were investigated. The results reveal that Ba-doped ye’elimite reacts faster than the stoichiometric ye’elimite. With the increase of Ba/Ca ratio, it can gradually increase the intensity of the initial peak, shorten the dormant period and reduce the total hydration heat. The phase composition evolution based on Rietveld/XRD method demonstrates that the dissolution rate of the C3.5B0.5A3$and C3BA3$ are about 19% and 28% higher than that of C4A3$ in 6h. Moreover, the hydration sequences and main products varied significantly. The AFt is absent for the system with barium incorporation and AFm tends to be less with the increase of Ba/Ca ratio. This paper also proposes a new acceleration mechanism of Ba-doped ye’elimite. It is summarized as a higher rate of dissolution-precipitation reaction stemmed from higher ion precipitation of BaSO4 and a combination of extra surface for the nucleation sites provided by BaSO4.This work is supported by the National Key Research and Development Plan of China (No. 2018YFD1101003 and No. 2016YFB0303505), National Natural Science Foundation of China (No. U1806222, 51602126, and 51761145023), Key Laboratory of Advanced Civil Engineering Materials (Tongji University), Ministry of Education (202001), the Taishan Scholars Program, Case-by-Case Project for Top Outstanding Talents of Jinan, Youth Innovation Support Program of Shandong Colleges and Universities (2019KJA017), State Key Laboratory of Silicate Materials for Architectures (Wuhan University of Technology) (No. SYSJJ2018-12)